By Howard Levine (hlevine
bptc
com) and Patti Seymour (pseymourbptccom)
Recent moves by Congress to repeal the healthcare reform act of 2010 (Patient Protection and Affordable Care Act [PPACA]) threaten to wipe out a pathway for the introduction of biosimilars in the US (Biologics Price Competition and Innovation Act [BPCIA]).
